The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Efficacy of PARP inhibitors in the treatment of AML
Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses the use of poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of acute myeloid leukemia (AML). Dr Wang first explains some background information on the promising activity of PARP inhibitors, and then discusses the potential use of these inhibitors to enhance the effectiveness of conventional chemotherapies. Dr Wang then draws focus on some results which demonstrated that the PARP inhibitor talazoparib is able to enhance the effect of venetoclax, and the promising applications that these findings may have in future triplet combinations for the treatment of AML. This interview took place at the 63rd ASH Annual Meeting and Exposition congress, Atlanta, GA, 2021.
